In a healthy knee, a firm, rubbery material called cartilage covers the end of the femur (thigh bone) and the tibia (shin bone). Cartilage provides a smooth, gliding surface for joint motion and acts as a cushion between the bones.1
When osteoarthritis affects the knee joint, oftentimes inflammation and tissue degeneration occur. This inflammation and tissue breakdown create a degenerative feedback loop, resulting in pain, deformity, and loss of function.1
ReNu is a cryopreserved amniotic suspension allograft, consisting of micronized amniotic membrane and amniotic fluid cells. The amniotic membrane is the inner layer of the placenta, which surrounds and protects the fetus and acts as a barrier between the mother and the baby.2 Amniotic tissue has been used successfully in medical care for more than 100 years.2
ReNu contains multiple anti-inflammatory cytokines and regenerative growth factors, which are found natively in human amniotic tissues.2,3 ReNu also contains amniotic fluid cells4, extracellular matrix (ECM) proteins5, and hyaluronic acid (a substance that acts as a lubricant and is naturally present in adult joints).2,5
If you have been diagnosed with OA and have been experiencing symptoms such as pain or discomfort, ReNu may be right for you. If you want to avoid taking oral treatments, such as NSAIDS, or stay away from the potentially damaging long-term side effects of corticosteroid injections7,8, or simply haven't experienced sufficient relief from other options, you should consider talking with your doctor about ReNu. ReNu is different. It's long-lasting OA symptom relief that really goes the distance.
A single injection of ReNu may result in a reduction of symptoms for up to 12 months.9,10,11
In a 200-patient randomized, single-blinded clinical trial, 69.1% of patients who received a ReNu injection had meaningful improvement of symptoms for at least 6 months.10 On average, patients who responded to ReNu had a 63% reduction in pain measured by the Visual Analog Score (VAS).11
The amniotic tissues in ReNu are collected from fully consented mothers undergoing scheduled caesarean section births of full-term healthy babies. Donors are tested for relevant communicable diseases by an FDA registered laboratory, and Organogenesis only releases tissue for transplantation that has negative or non-reactive results for all tested communicable diseases. After screening, the amniotic tissue is aseptically processed in a controlled, clean environment following strict technical quality assurance standards.6